Sun Pharma Advanced Research Company Ltd.
ShareSPARC Competitor Analysis
| SPARC | SUNPHARMA  | DIVISLAB | TORNTPHARM | CIPLA | |
|---|---|---|---|---|---|
Overview | |||||
| Current price (₹) As on 30 Sept, 2025, 03:49 PM | 129.52 0.57% | 1,594.30 0.31% | 5,689.50 -0.14% | 3,603.20 0.46% | 1,503.30 1.03% |
| Market cap (₹ Cr) | 4,203 | 3,82,526 | 1,51,038 | 1,21,949 | 1,21,430 |
Report Card | |||||
| Quality | |||||
| Growth | |||||
| Momentum | |||||
| Value | |||||
Past ReturnsAbsolute Returns Shown | |||||
| 1D | 0.57% | 0.31% | -0.14% | 0.46% | 1.03% |
| 1W | -7.08% | -2.26% | -5.97% | -1.32% | -1.56% |
| 1M | -7.55% | -0.01% | -7.21% | 1.22% | -5.42% |
| 3M | -20.24% | -4.86% | -16.45% | 5.72% | -0.17% |
| 6M | -12.43% | -8.09% | -1.49% | 11.63% | 4.24% |
| 1Y | -40.02% | -17.25% | 4.52% | 6.08% | -9.12% |
| 5Y | -25.43% | 218.57% | 86.67% | 157.38% | 94.05% |
Income StatementAnnual data as on 30 Sept 2025. All values in ₹ Cr. YoY growth displayed | |||||
| Sales | 71.77 -5% | 52,578 8.41% | 9,360 19.31% | 11,516 7.35% | 27,548 6.88% |
| OPM (%) | -439.3 -14.73% | 28 7.2% | 30.56 13.44% | 32.25 3.3% | 25.09 5.78% |
| PBT | -342.78 11.39% | 13,752 24.03% | 2,916 34.81% | 2,673 13.65% | 6,821 19.62% |
PAT | -342.51 11.54% | 10,980 13.81% | 2,191 36.94% | 1,911 15.4% | 5,291 27.34% |
| Net Profit Margin | -477.26 6.89% | 20.85 5.2% | 23.41 14.75% | 16.6 7.51% | 19.13 18.67% |
| EPS | -10.55 11.57% | 45.55 14.13% | 82.53 36.93% | 56.47 15.39% | 65.28 27.87% |
Balance Sheet & Cash FlowAnnual data as on 30 Sept 2025. All values in ₹ Cr. YoY growth displayed | |||||
| Net Worth | -216.95 -272.51% | 72,218 13.43% | 14,969 10.3% | 7,591 10.72% | 31,193 16.8% |
| Total Assets | 335.53 -34.85% | 92,101 7.77% | 16,932 9.45% | 14,990 -0.47% | 37,387 14.27% |
| Total Outside Liabilities | 552.48 41.92% | 19,883 -8.78% | 1,963 3.37% | 7,399 -9.81% | 6,194 3.04% |
| Cash from Operating Activity | -360.29 16.05% | 14,072 15.96% | 1,653 31.09% | 2,585 -20.85% | 5,005 21.07% |
| Cash from Investment Activity | 157.66 -59.73% | -5,306 -668.76% | -804 -198.88% | -540.05 -221.65% | -3,691 -23.53% |
| Cash from Financing Activity | 199.26 369.84% | -7,906 -17.82% | -799 0% | -2,298 17.34% | -1,293 -7.75% |
| Net Cash Flow | -3.37 -170.95% | 983.12 -78.91% | 50 -74.09% | -261.66 -180.11% | 30.31 161.87% |
RatiosAnnual data as on 30 Sept 2025. | |||||
| PB | N.A. | 5.77 | 10.22 | 14.42 | 3.73 |
| PE | N.A. | 35.00 | 68.94 | 63.81 | 23.03 |
| ROE (%) | 0 | 16.16 | 15.35 | 26.46 | 18.28 |
| Dividend Yield (%) | 0 | 1.00 | 0.53 | 0.89 | 1.06 |
| ROCE (%) | 0 | 20.86 | 20.45 | 27.55 | 23.64 |
